POPULARITY
Categories
142 episodes with Microlearning
33 episodes with Microlearning
221 episodes with Microlearning
11 episodes with Microlearning
9 episodes with Microlearning
10 episodes with Microlearning
10 episodes with Microlearning
4 episodes with Microlearning
5 episodes with Microlearning
9 episodes with Microlearning
4 episodes with Microlearning
5 episodes with Microlearning
4 episodes with Microlearning
2 episodes with Microlearning
4 episodes with Microlearning
3 episodes with Microlearning
4 episodes with Microlearning
3 episodes with Microlearning
When NDIS support workers understand the rights of the people they care for, the care changes. Zoe and Karen are joined by Liz Sakal — Ausmed's Disability Team Lead, who led the team behind the Know My Rights project: a national micro-learning platform built in partnership with Inclusion Australia and funded by the NDIS Quality and Safeguards Commission Grant Program. They cover how 15 micro-learning modules were built around five cohorts in the NDIS community, the co-design process that shaped every module and the Generative Learning Experiences that lets participants rehearse advocacy conversations freely. Know It. Show It. Act On It. Contact the show at podcast@ausmed.com.au Follow us on Linkedin → Zoe, Michelle, Karen Follow Ausmed on LinkedIn, Facebook & Instagram Resources: Know My Rights | NDIS Micro-learning Platform Register for Upcoming Webinars | NDIS Provider Capability Series About KMR by Will Egan | Ausmed Stories Learn More About Ausmed: https://lnk.bio/ausmed/organisationsSee omnystudio.com/listener for privacy information.
Featuring an interview with Prof Bernd Kasper, including the following topics: Case: A woman in her early 30s develops a progressing desmoid tumor in her abdomen during pregnancy(0:00) Case: A woman in her late 30s with a painful small desmoid tumor in her rectus abdominus undergoes cryoablation (8:04) Case: A woman in her late teens with recurrent desmoid tumors in her right thigh undergoes multiple resections (13:58) Case: A woman in her mid 70s has a desmoid tumor causing erosion in her scapular region (17:19) CME information and select publications
Microsoft Copilot in Microsoft 365 kann Dir heute schon E-Mails, Kalender und Dateien abnehmen – wenn Du ihn richtig nutzt. In dieser Interview-Folge mit Florian Sandmann-Reetz bekommst Du konkrete Workflows, die sofort Zeitfresser® und Geldfresser® stoppen. In dieser Episode hörst Du, wie Du KI im Mittelstand wirklich produktiv einsetzt, wenn:
Interview conducted with Prof Bernd Kasper on March 5, 2026, by Dr Neil Love, including the following topics: Current management of desmoid tumors: A review from the Desmoid Tumor Working Group (0:00) Long-term nirogacestat treatment in adult patients with desmoid tumors: Updated efficacy and safety from the Phase III DeFi trial (8:26) Phase IV trial of nirogacestat in adult premenopausal women with desmoid tumors (17:35) CME information and select publications here.
What does it take to deliver impactful learning in a global, highly regulated industry? Tim Greiner, Senior Director of USP Education at the U.S. Pharmacopeia, a global nonprofit that sets quality standards for medicines, food, and dietary supplements, shares how USP delivers education at scale to ensure those standards are applied effectively across industries and regions to improve quality and protect public health. Show Notes:Senior Education Director Tim Greiner explains how USP delivers training that improves quality and performance. Key takeaways from the conversation include:Impact over completion: In regulated environments, training success is measured by behavior change and improved quality practices—not just course completion. Design for diverse, global audiences: Effective programs balance modalities, regional preferences, and roles (regulators, manufacturers, students) without overcomplicating delivery. Blended learning drives stronger outcomes: Live and live-virtual experiences tend to have the highest impact, especially when paired with self-paced resources for reinforcement. Operational discipline matters at scale: Managing global training requires strong processes—centralized content, regular reviews, and alignment with evolving standards. Microlearning in the flow of work is the future: Delivering targeted learning at the exact moment of need can significantly increase retention, application, and overall impact. Powered by Learning earned Awards of Distinction in the Podcast/Audio and Business Podcast categories from The Communicator Awards and a Gold and Silver Davey Award. The podcast is also named to Feedspot's Top 40 L&D podcasts and Training Industry's Ultimate L&D Podcast Guide. Learn more about d'Vinci at www.dvinci.com. Follow us on LinkedInLike us on Facebook
Featuring proceedings from a live event on January 9, 2026, held adjunct to the 2026 ASCO Gastrointestinal Cancers Symposium and moderated by Dr Samuel J Klempner, including the following topics: Treatment approach for metastatic HER2-negative, claudin 18.2-positive, microsatellite instability-high gastroesophageal (GE) cancer (0:00) Duration of chemotherapy for patients with advanced GE cancers receiving nivolumab/chemotherapy (3:06) Younger patient with metastatic PD-L1-positive gastric cancer (5:29) CME information and select publications
Feedback, both recieving and giving are so important at work. We will go through a few points in this episodeFeedback is not just what you say, but when and how you say it.Intent without clarity creates confusion.Respect determines whether feedback is heard or resisted.Specific feedback is more useful than vague criticism.Trust makes honesty possible.You can email me at AgileMalayali@gmail.com and connect on LinkedIn https://www.linkedin.com/in/vinodn/ You can also join our Telegram Learning GroupAlso checkout my other Podcasts Other PodcastsPahayan Talks Malayalam PodcastVayanalokam Malayalam Book PodcastEnglish Podcast Penpositive OutclassYouTube ChannelsPahayan Talks Youtube ChannelAgile Malayali YouTube ChannelPenpositive YouTube Channel
Education is key to preventing damage to underground infrastructure and keeping workers and communities safe. In this episode, Common Ground Alliance's Erika Lee and Lisa O'Leary share how their Excavator Damage Prevention curriculum is using data-driven training to change behavior and reduce risk.Show Notes:CGA's Erika Lee and Lisa O'Leary discuss how their comprehensive training curriculum is tackling the root causes of damage through education, accessibility, and industry collaboration. Their key points include:Education is the first line of defense against excavation damage: Erika Lee emphasized that if workers don't understand risks and best practices, “we're really not setting them up for success.”Failure to contact 811 remains the leading cause of damage: The top root cause year over year is not calling 811 before digging—highlighting a major opportunity for behavior change.Up to 65% of damage incidents are preventable through behavior change: The majority of incidents are tied to excavator actions that can be improved through targeted training, according to Erika.Microlearning and accessibility are key to adoption: Lisa O'Leary shared that short, 5–7 minute modules and mobile-friendly access make it easier for workers in the field to engage with training.Collaboration and consensus drive better outcomes: Common Ground Alliance's consensus-based approach ensures diverse stakeholders align on best practices—strengthening both the curriculum and industry impact.Learn more about Common Ground Alliance's education program. Explore d'Vinci's work with Common Ground Alliance. Powered by Learning earned Awards of Distinction in the Podcast/Audio and Business Podcast categories from The Communicator Awards and a Gold and Silver Davey Award. The podcast is also named to Feedspot's Top 40 L&D podcasts and Training Industry's Ultimate L&D Podcast Guide. Learn more about d'Vinci at www.dvinci.com. Follow us on LinkedInLike us on Facebook
Starting is very common but finishing is not. We will go through a few points in this videoStarting is driven by excitement; finishing is driven by discipline.Many people collect beginnings but avoid endings.Half-finished work drains mental energy.Completion creates real value, not intention.Confidence grows when you consistently finish what you start.You can email me at AgileMalayali@gmail.com and connect on LinkedIn https://www.linkedin.com/in/vinodn/ You can also join our Telegram Learning GroupAlso checkout my other Podcasts Other PodcastsPahayan Talks Malayalam PodcastVayanalokam Malayalam Book PodcastEnglish Podcast Penpositive OutclassYouTube ChannelsPahayan Talks Youtube ChannelAgile Malayali YouTube ChannelPenpositive YouTube Channel
Dr Stacey A Cohen from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Jenny Seligmann from the University of Leeds in the United Kingdom and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora review clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium relevant to the management of localized colorectal cancer. CME information and select publications here.
Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics: Role of circulating tumor DNA (ctDNA) testing in the escalation of treatment for Stage II and deescalation for Stage III colon cancer (0:00) Impact of timing on the clinical relevance of ctDNA minimal residual disease test results in localized colorectal cancer (8:58) Approach to managing Stage III colon cancer with ctDNA-positive results after adjuvant treatment (13:35) CME information and select publications
Asking better questions is a key aspect of work. We will go through three points in this videoQuestions shape how we think about problems.Good questions reveal systems and relationships.Curiosity creates clarity.You can email me at AgileMalayali@gmail.com and connect on LinkedIn https://www.linkedin.com/in/vinodn/ You can also join our Telegram Learning GroupAlso checkout my other Podcasts Other PodcastsPahayan Talks Malayalam PodcastVayanalokam Malayalam Book PodcastEnglish Podcast Penpositive OutclassYouTube ChannelsPahayan Talks Youtube ChannelAgile Malayali YouTube ChannelPenpositive YouTube Channel
Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics: Role of PD-L1 status, tumor histology and pulmonary disease in selection of immune checkpoint inhibition as up-front therapy (0:00) Impact of metastatic site and autoimmune disease on clinical decision-making in the use of immune checkpoint inhibition (5:56) Biomarker assessment approach and treatment selection (10:50) CME information and select publications
Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Samuel Klempner from Massachusetts General Hospital in Boston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, and Dr John Strickler from Duke University in Durham, North Carolina, review relevant data supporting immunotherapy for patients with gastroesophageal cancers and review recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium. CME information and select publications here.
There is a link we create between success and our identity and this might be a dangerous link.You can email me at AgileMalayali@gmail.com and connect on LinkedIn https://www.linkedin.com/in/vinodn/ You can also join our Telegram Learning GroupAlso checkout my other Podcasts Other PodcastsPahayan Talks Malayalam PodcastAgile Indian English PodcastVayanalokam Malayalam Book PodcastCinema Malayali Malayalam PodcastEnglish Podcast Penpositive OutclassYouTube ChannelsPahayan Talks Youtube ChannelAgile Malayali YouTube ChannelPenpositive YouTube ChannelAgile Positive Your Tube ChannelAgile Indian YouTube Channel
Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics: Adjuvant treatment planning for Stage II or III microsatellite instability-high colon cancer (0:00) Roles of circulating tumor DNA (ctDNA), POLE mutations and advanced age in adjuvant treatment planning (6:08) Role of ctDNA in adjuvant treatment planning for Stage III colon cancer (12:31) CME information and select publications
Dr Stacey A Cohen from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Jenny Seligmann from the University of Leeds in the United Kingdom and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora review clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium relevant to the management of localized colorectal cancer.CME information and select publications here.
Featuring perspectives from Dr Paul G Richardson, including the following topics: EXCALIBER-RRMM: A Phase III trial of iberdomide, daratumumab and dexamethasone for relapsed/refractory multiple myeloma (0:00) Lonial S et al. EXCALIBER-RRMM: A phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. Future Oncol 2025;21(14):1761-9. Abstract Phase III SUCCESSOR-1 and SUCCESSOR-2 studies evaluating mezigdomide-based regimens for relapsed/refractory multiple myeloma (8:24) Richardson PG et al. A phase III, two-stage, randomized study of mezigdomide, bortezomib, and dexamethasone (MeziVd) versus pomalidomide, bortezomib, and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-1. SOHO 2023;Abstract MM-372. Richardson PG et al. A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2. ASCO 2023;Abstract TPS8070. EMN26: A Phase II study of maintenance therapy with iberdomide after autologous stem-cell transplantation for newly diagnosed multiple myeloma (13:34) van de Donk NWCJ et al. Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial. ASH 2025;Abstract 101. STOMP: A Phase I study of selinexor, mezigdomide and dexamethasone for patients with relapsed/refractory multiple myeloma who experienced relapse with or are ineligible for T-cell-redirecting therapy (24:53) Mo C et al. Selinexor, mezigdomide, and dexamethasone in patients with relapsed/refractory multiple myeloma who relapsed or are ineligible for T-cell–redirecting therapy: Stomp Phase 1 results. ASH 2025;Abstract 4010. CME information and select publications
Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.CME information and select publications here.
Featuring perspectives from Dr Haley Ellis, Prof Eric Van Cutsem and Dr Zev Wainberg, moderated by Dr Lionel A Kankeu Fonkoua, including the following topics: Gastroesophageal cancer (0:00) Recurrent colorectal cancer (5:43) Colorectal cancer with brain metastases (9:59) CME information and select publications
Dr Haley Ellis from Harvard Medical School in Boston, Massachusetts, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, Dr Zev Wainberg from UCLA School of Medicine in Los Angeles, California, and moderator Dr Lionel A Kankeu Fonkoua from Mayo Clinic in Rochester, Minnesota, discuss recent data surrounding the management of HER2-positive GI cancers, alongside their perspectives on its clinical application and management.CME information and select publications here.
Featuring an interview with Dr Ravin Ratan, including the following topics: Case: A woman in her early 40s who develops intense nausea and vomiting and is diagnosed with a pelvic desmoid tumor elects surveillance and experiences spontaneous regression of the tumor (0:00) Case: A woman in her late 30s with a painful desmoid tumor in the right pelvic wall receives cryoablation because of concerns about ovarian function (6:49) Case: A woman in her early 40s with breast implants and multiple resections of breast desmoid tumors receives nirogacestat for 2 years with positive response but develops mucositis and Grade 1 asthenia and stops treatment (14:10) Case: A woman in her mid 30s with a history of gastric sleeve and endometriosis presents with a painful desmoid tumor in the left upper quadrant, receives nirogacestat with headaches and gastrointestinal symptoms that improve over time and experiences a decrease in tumor size (21:27) CME information and select publications
Most safety training is easy to forget – because it's designed to be delivered, not retained. In this episode, Mark Woodward, Director of Training and Safety Manager at Sellenriek Construction, shares how microlearning turns workplace training into a tool that actually changes behavior, builds consistency, and shows up in safety outcomes over time.
Dr Ravin Ratan from The University of Texas MD Anderson Cancer Center in Houston discusses available clinical data with treatment approaches for desmoid tumors, alongside clinical cases illustrating real-world application.CME information and select publications here.
Dr Ravin Ratan from The University of Texas MD Anderson Cancer Center in Houston discusses available clinical data with treatment approaches for desmoid tumors, alongside clinical cases illustrating real-world application.CME information and select publications here.
Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics: Older patient with metastatic claudin 18.2-positive gastroesophageal (GE) cancer (0:00) Management of nausea and vomiting with zolbetuximab for GE cancer (9:37) Younger patient with metastatic claudin 18.2-positive, PD-L1-positive GE cancer (15:34) CME information and select publications
Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Samuel Klempner from Massachusetts General Hospital in Boston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, and Dr John Strickler from Duke University in Durham, North Carolina, review relevant data supporting immunotherapy for patients with gastroesophageal cancers and recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.CME information and select publications here.
Featuring an interview with Dr Hanny Al-Samkari, including the following topics: Case: A man in his early 40s with chronic immune thrombocytopenia (ITP) receives romiplostim with rituximab — Bhavana (Tina) Bhatnagar, DO (0:00) Case: A woman in her early 80s with metastatic adenocarcinoma of the lung responds to carboplatin/pemetrexed/pembrolizumab but after 14 months of maintenance pembrolizumab presents with ITP — Susmitha Apuri, MD (6:48) Case: A man in his late 70s with a 30-year history of chronic ITP who received corticosteroids and rituximab now receives avatrombopag — Sunil Gandhi, MD (12:06) Case: A woman in her early 80s with multiple comorbidities and a long history of ITP presents with confusion and fluid retention due to exacerbated congestive heart failure and receives fostamatinib — Dr Bhatnagar (19:26) CME information and select publications
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.CME information and select publications here.
Why Your Performance Should Not Define YouYou can email me at AgileMalayali@gmail.com and connect on LinkedIn https://www.linkedin.com/in/vinodn/ You can also join our Telegram Learning GroupAlso checkout my other Podcasts Other PodcastsPahayan Talks Malayalam PodcastAgile Indian English PodcastVayanalokam Malayalam Book PodcastCinema Malayali Malayalam PodcastEnglish Podcast Penpositive OutclassYouTube ChannelsPahayan Talks Youtube ChannelAgile Malayali YouTube ChannelPenpositive YouTube ChannelAgile Positive Your Tube ChannelAgile Indian YouTube Channel
Microlearning accelerates Gen AI education by delivering flexible, role-based, bite-sized training that boosts productivity, drives innovation, and builds a culture of continuous learning without disrupting daily operations. That's the key take-away message of this episode of the Wise Decision Maker Show, which discusses how microlearning offers a flexible approach to Gen AI education.This article forms the basis for this episode: https://disasteravoidanceexperts.com/microlearning-offers-a-flexible-approach-to-gen-ai-education/
Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics: Neoadjuvant immunotherapy for localized rectal cancer (0:00) Surveillance in neoadjuvant immunotherapy for localized rectal cancer (8:14) Determining a treatment strategy for resectable colon cancer (12:35) CME information and select publications
Dr Stacey A Cohen from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Jenny Seligmann from the University of Leeds in the United Kingdom and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora review clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium relevant to the management of localized colorectal cancer.CME information and select publications here.
Dr Stacey A Cohen from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Jenny Seligmann from the University of Leeds in the United Kingdom and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora review clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium relevant to the management of localized colorectal cancer.CME information and select publications here.
Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics: Younger patient with metastatic HER2-positive, PD-L1-positive gastric cancer (0:00) Older patient with metastatic HER2-positive gastroesophageal (GE) cancer (8:13) Clinical applications for zanidatamab in GE cancer (13:58) CME information and select publications
Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, Dr John Strickler from Duke University in Durham, North Carolina, and moderator Dr Samuel Klempner from Massachusetts General Hospital in Boston review relevant data supporting immunotherapy for patients with gastroesophageal cancers and review recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.CME information and select publications here.
Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, Dr John Strickler from Duke University in Durham, North Carolina, and moderator Dr Samuel Klempner from Massachusetts General Hospital in Boston review relevant data supporting immunotherapy for patients with gastroesophageal cancers and review recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.CME information and select publications here.
Featuring perspectives from Dr Paul G Richardson, including the following topics: Mechanism of action and pharmacology of cereblon E3 ligase modulators (0:00) Available efficacy data (4:54) Extramedullary disease (10:51) Side effects and toxicity (16:58) CME information and select publications
Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.CME information and select publications here.
Featuring an interview with Dr Hanny Al-Samkari, including the following topics: Case: A woman in her early 70s incidentally diagnosed with immune thrombocytopenia (ITP) experiences a suboptimal response to prednisone and IVIG — Bhavana (Tina) Bhatnagar, DO (0:00) Case: A man in his early 50s with a long history of ITP undergoes splenectomy — Neil Morganstein, MD (5:06) Case: A woman in her mid 50s with symptomatic iron-deficiency anemia who was found to have ITP has received corticosteroids, rituximab and IVIG — Jennifer Yannucci, MD (12:25) Case: A woman in her early 30s who previously received ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) and autologous stem cell transplant for Hodgkin lymphoma is diagnosed with ITP 5 years later that is refractory to high-dose prednisone, IVIG and rituximab, then romiplostim — Priya Rudolph, MD, PhD (18:19) CME information and select publications
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.CME information and select publications here.
Featuring perspectives from Dr Haley Ellis, Prof Eric Van Cutsem and Dr Zev Wainberg, moderated by Dr Lionel A Kankeu Fonkoua, including the following topics: Novel immune checkpoint inhibitors (0:00) Gastroesophageal junction cancer (7:36) Gastric cancer (14:52) CME information and select publications
Featuring an interview with Dr Ravin Ratan, including the following topics: Efficacy and safety of long-term continuous nirogacestat treatment in adults with desmoid tumors: Results from the Phase III DeFi trial (0:00) Onset and resolution of ovarian toxicity with nirogacestat treatment for desmoid tumors: Updated safety analyses from the DeFi trial (4:37) Subgroup analysis of the Phase II part of the RINGSIDE Phase II/III trial of varegacestat for desmoid tumors (7:39) Surgical management of desmoid tumors; cryotherapy in the treatment of extra-abdominal desmoid tumors (10:30) CME information and select publications
Dr Ravin Ratan from The University of Texas MD Anderson Cancer Center in Houston discusses available clinical data with treatment approaches for desmoid tumors, alongside clinical cases illustrating real-world application.CME information and select publications here.
Featuring perspectives from Dr Haley Ellis, Prof Eric Van Cutsem and Dr Zev Wainberg, moderated by Dr Lionel A Kankeu Fonkoua, including the following topics: Biliary tract cancer progressing on first-line therapy (0:00) Gallbladder cancer (5:01) Biliary tract cancer with multiple biomarker targets (8:52) CME information and select publications
Featuring an interview with Dr Hanny Al-Samkari, including the following topics: VAYHIT1: A multicenter randomized, double-blind, Phase III trial evaluating ianalumab versus placebo in addition to first-line corticosteroids for patients with primary immune thrombocytopenia (ITP) (0:00) Secondary analysis results from VAYHIT3, a Phase II study of ianalumab for patients with primary ITP previously treated with at least 2 lines of therapy (8:15) Improved health-related quality of life and bleeding scores with the oral Bruton tyrosine kinase inhibitor rilzabrutinib in the open-label period of the multicenter Phase III LUNA 3 study for adults with ITP (12:23) Romiplostim for chemotherapy-induced thrombocytopenia in patients with colorectal, gastroesophageal and pancreatic cancer: A global Phase III randomized, placebo-controlled trial (16:01) CME information and select publications
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.CME information and select publications here.
What happens when 50 million people need endocrine care… but there are only about 4,000 practicing endocrinologists to see the complex cases? In an environment where misinformation is everywhere and specialist capacity is limited, how can an association help clinicians and care teams deliver better outcomes at scale without diluting quality?In this episode of Associations Thrive, host Joanna Pineda interviews Johnnie White, CEO of the American Association of Clinical Endocrinology (AACE). Johnnie discusses:How AACE's membership is ~6,000 worldwide, with predominantly physicians and a growing “endocrine care team” that includes NPs, PAs, pharmacists, and primary care clinicians.The sobering workforce math: “there's not enough endocrinologists” for the volume of diabetes (and other endocrine disorders), and why AACE prioritizes educating the broader care team.How members get access to endocrine-specific education, guidelines, publications, and networking with field experts.The strategic shift from “endocrinologists” to “endocrinology” and how a bigger tent supports care delivery while keeping endocrinologists as the clinical leaders who develop guidelines.AACE's patient-first digital strategy: landing visitors on the patient portal first, then routing clinicians to the healthcare/member portal.How AACE built “patient journeys” (diabetes, thyroid, obesity, and more) to counter misinformation and provide understandable, trustworthy guidance for patients and caregivers.Why AACE's patient content is heavily used not only by patients but also by clinicians who refer patients to it for education and reinforcement.The organization's non-traditional education mix, including podcasts as an accessible channel for timely topics, and microlearning with short modules, tracked for continuing education credit.Johnnie's leadership philosophy, “Mamba Mentality,” is a continuous quest to improve, seek feedback, and empower experts on the team.References:AACE Website
Since 2014, the L&D Global Sentiment Survey has been a barometer of what's hot and what's not in the Learning & Development profession, guiding people development professionals towards the trends that their peers are most concerned about. In this episode, Donald H Taylor takes a deep dive into the 2026 report and explores in conversation what we should all be taking note of. Take your L&D to the next level Take advantage of thousands of hours of analysis. Hundreds of conversations with industry innovators and 25+ years of hands-on global L&D leadership. It's all distilled into one framework to help you level up L&D. Access the L&D Maturity Model here - https://360learning.com/maturity-model KEY TAKEAWAYS The strongest route to security and impact for L&D is finding real business problems through your network, then designing simple, targeted interventions that change behaviour and performance—whether or not the answer looks like traditional training. L&D cannot afford to anchor it's worth to content production. If it does it risks being commoditised instead of recognised for solving real business problems. AI is more powerful than we thought, it is helping to deliver truly personalised training. Microlearning may feel like “old news” in some markets, but the survey shows it's still emerging and powerful elsewhere. A reminder that L&D practices move at very different speeds across the world. BEST MOMENTS “The future is going to belong to people who understood early on what worked and what didn't work.” “The wrong turn is to go towards focusing on content.” Donald H Taylor Bio A recognised commentator and thinker in the fields of workplace learning and supporting technologies, Donald is committed to helping develop the learning and development profession. Donald has chaired the Learning Technologies Conference in London since 2000 and writes and speaks world-wide about Learning and Development (L&D). His annual L&D Global Sentiment Survey, started in 2014, provides a unique perspective on L&D trends from over 100 countries. He chairs the Workforce Development board for VC firm Emerge Education, and invests in, and advises, several EdTech start-ups. From 2010 to 2021, he chaired the Learning and Performance Institute. He is the author of Learning Technologies in the Workplace, a graduate of Oxford University and in 2016 was awarded an honorary doctorate by Middlesex University in recognition of his work developing the L&D profession. You can follow and contact Donald via: LinkedIn: https://www.linkedin.com/in/donaldhtaylor/ L&D Global Sentiment Survey 2026: https://donaldhtaylor.co.uk/research_base/global-sentiment-survey-2026/ Website: https://donaldhtaylor.co.uk/ VALUABLE RESOURCES The Learning And Development Podcast - https://podcasts.apple.com/gb/podcast/the-learning-development-podcast/id1466927523 L&D Master Class Series: https://360learning.com/blog/l-and-d-masterclass-home ABOUT THE HOST David James David has been a People Development professional for more than 20 years, most notably as Director of Talent, Learning & OD for The Walt Disney Company across Europe, the Middle East & Africa. As well as being the Chief Learning Officer at 360Learning, David is a prominent writer and speaker on topics around modern and digital L&D. CONTACT METHOD Twitter: https://twitter.com/davidinlearning LinkedIn: https://www.linkedin.com/in/davidjameslinkedin L&D Collective: https://360learning.com/the-l-and-d-collective Blog: https://360learning.com/blog L&D Master Class Series: https://360learning.com/blog/l-and-d-masterclass-home This Podcast has been brought to you by Disruptive Media. https://disruptivemedia.co.uk/
© 2020-2026 Ivy Podcast Discovery LLC
